Peter Attia· MD
Doctors often reluctant to tell you your APOE genotype as they say “there is nothing you can do anyway”
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
Doctors often reluctant to tell you your APOE genotype as they say “there is nothing you can do anyway”
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
so even though 25% of the population has a pony for positive gene meaning they're either one or two copies of a pony and most of those 25% are single copy they make up about two-thirds of the case of Alzheimer's diseases but of course that means 75% of people who don't have any efore still make up a third of the cases
it is typically not something that we check for in a routine day-to-day clinical care for a couple of reasons one is it's not diagnostic right so you can have e4 e4 and not have alzheimer's or you can have e2 e3 which might be protective and still have alzheimer's
not really i mean it's really more about the genotyping than the quantification of it you know obviously and again you've talked about it on prior podcasts the um the risk that e4 genotype carries compared to the others